Germany · Delayed Price · Currency is EUR BioLife Solutions Company Description
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals.
It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
| Country | United States |
| Founded | 1987 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 159 |
| CEO | Roderick de Greef |
Contact Details
Address: 3303 Monte Villa Parkway Bothell, Delaware 98021 United States | |
| Phone | 425 402 1400 |
| Website | biolifesolutions.com |
Stock Details
| Ticker Symbol | BJX1 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Roderick de Greef | Chief Executive Officer |
| Troy Wichterman | Chief Financial Officer |
| Karen Foster | Chief Operating Officer |